Terapevticheskii arkhiv · 2003
[Use of clonazepam for treatment of patients with paroxysmal atrial fibrillation with regard to their psychoautonomic status].
Аннотация на английскомСтатьяНазвание и аннотация: Оригинал на русском
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nedostup A V, Solov'eva A D, San'kova T A
Аннотация
AIM: To study the efficacy of clonazepam in patients with paroxysmal atrial fibrillation (PAF) with reference to their psychovegetative status.
MATERIAL AND METHODS: 50 patients with PAF of non-rheumatic origin entered the study group, 20 healthy examinees served control. All of them were examined using a clinicocardiological, cliniconeurological tests; their autonomic nervous system, emotional sphere, sleep disorders were studied before and after clonazepam treatment in a dose 0.5 mg 2 times a day for 30 days.
RESULTS: A positive effect of clonazepam was noted in 20 (80%) patients with PAF, less frequent paroxysms occurred in 12 (48%) patients, in 5 patients they stopped, 12 (48%) patients tolerated the paraxysms better. The paraxysms became shorter in 10 (40%) patients, 10 (40%) patients felt better in the postparoxysmal period. A marked relief of psychovegetative syndrome, improvement of activity, mood and quality of sleep were noted in all the patients.
CONCLUSION: Clonazepam is recommended for patients with PAF to improve antiarrhythmia therapy.
MATERIAL AND METHODS: 50 patients with PAF of non-rheumatic origin entered the study group, 20 healthy examinees served control. All of them were examined using a clinicocardiological, cliniconeurological tests; their autonomic nervous system, emotional sphere, sleep disorders were studied before and after clonazepam treatment in a dose 0.5 mg 2 times a day for 30 days.
RESULTS: A positive effect of clonazepam was noted in 20 (80%) patients with PAF, less frequent paroxysms occurred in 12 (48%) patients, in 5 patients they stopped, 12 (48%) patients tolerated the paraxysms better. The paraxysms became shorter in 10 (40%) patients, 10 (40%) patients felt better in the postparoxysmal period. A marked relief of psychovegetative syndrome, improvement of activity, mood and quality of sleep were noted in all the patients.
CONCLUSION: Clonazepam is recommended for patients with PAF to improve antiarrhythmia therapy.